Patents by Inventor MYEONG OK KIM

MYEONG OK KIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240352528
    Abstract: A microRNA biomarker is for early diagnosis of mild cognitive impairment or Alzheimer type dementia. The microRNA biomarker includes miRNAs of SEQ ID NOs: 1 to 5 obtained by molecule-based analysis are expressed in the blood plasma of patients with mild cognitive impairment or Alzheimer type dementia. The miRNAs have an effect of reducing the expression of proteins that are related to mild cognitive impairment or Alzheimer type dementia. As such, the early diagnosis of mild cognitive impairment or Alzheimer type dementia is enabled before symptoms appear by utilizing a novel miRNA present in relatively non-invasive blood plasma as a diagnostic indicator.
    Type: Application
    Filed: August 11, 2022
    Publication date: October 24, 2024
    Inventors: MYEONG OK KIM, TAE JU PARK, HYUN YOUNG PARK
  • Publication number: 20220091138
    Abstract: The composition for predicting Alzheimer's disease prognosis comprising a detection reagent that specifically binds to any one or more genes selected from the group consisting of (Nitric oxide synthase 1), Aph1B (Anterior pharynx defective 1 homolog B), Ryr3 (Ryanodine receptor 3), Atf6 (Activating transcriptional factor 6), Ip3r (Inositol trisphosphate receptor), Nep (Neprilysin), Cdk5 (cyclin dependent kinase 5) and Abad (Amyloid beta-binding alcohol dehydrogenase), a kit, and a method for providing information on Alzheimer's disease prognosis of the present invention can rapidly and accurately predict the prognosis of Alzheimer's disease, and can determine the prognosis for a drug by comparing the expression level before and after drug administration, so that an appropriate treatment direction can be determined according to the predicted prognosis. Therefore, they have an effect that can greatly contribute to the reduction of mortality due to Alzheimer's disease.
    Type: Application
    Filed: June 15, 2020
    Publication date: March 24, 2022
    Applicant: Industry-Academic Cooperation Foundation Gyeongsang National University
    Inventor: Myeong Ok KIM
  • Patent number: 10618937
    Abstract: A method for preventing, improving or treating a neurological disorder includes administering to a subject a composition including an adiponectin receptor-activating novel peptide as an active ingredient. The adiponectin receptor-activating novel peptide is a peptide consisting of 5 amino acids, and when the adiponectin receptor-activating novel peptide is administered to Alzheimer's model mice, the mice's behavioral changes show that memory and cognitive functions are significantly increased, and APP and amyloid beta (A?) proteins are significantly reduced, cytotoxicity does not occur, the proliferation rate of neurons is increased, and cell death is inhibited.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: April 14, 2020
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventor: Myeong Ok Kim
  • Patent number: 10471119
    Abstract: A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: November 12, 2019
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventor: Myeong Ok Kim
  • Publication number: 20180312540
    Abstract: A method for preventing, improving or treating a neurological disorder includes administering to a subject a composition including an adiponectin receptor-activating novel peptide as an active ingredient. The adiponectin receptor-activating novel peptide is a peptide consisting of 5 amino acids, and when the adiponectin receptor-activating novel peptide is administered to Alzheimer's model mice, the mice's behavioral changes show that memory and cognitive functions are significantly increased, and APP and amyloid beta (A?) proteins are significantly reduced, cytotoxicity does not occur, the proliferation rate of neurons is increased, and cell death is inhibited.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 1, 2018
    Inventor: Myeong Ok KIM
  • Publication number: 20180036365
    Abstract: A method of preventing or treating neurological disease includes administering to a subject in need thereof, a composition comprising an osmotin peptide selected from the group consisting of (a) an osmotin peptide having the amino acid sequence of SEQ ID NO: 1, and (b) an osmotin peptide having at least one amino acid residue substitution, deletion or insertion in the amino acid sequence of SEQ ID NO: 1. When a subject is treated with the osmotin peptide, nerve cells show no increase in growth rate, have little cytotoxicity, and suppress cell death, and when the osmotin peptide is administered to an animal model, the osmotin peptide infiltrated into the hippocampus of the brain and the hypothalamus of the brain, which is the deep part of the brain. Accordingly, the osmotin peptide is used as a composition for preventing, ameliorating, or treating neurological disease.
    Type: Application
    Filed: March 3, 2016
    Publication date: February 8, 2018
    Inventor: Myeong Ok KIM
  • Publication number: 20170246245
    Abstract: The present invention relates to a pharmaceutical composition, and more specifically, to a novel pharmaceutical composition for treating Alzheimer's disease including osmotin as an active ingredient.
    Type: Application
    Filed: September 15, 2014
    Publication date: August 31, 2017
    Inventor: Myeong Ok KIM
  • Patent number: 9352018
    Abstract: The present invention relates to a composition for preventing and treating neurological diseases, and more particularly to a composition for preventing and treating neurological diseases comprising osmotin, a health functional food composition for preventing and ameliorating neurological diseases comprising osmotin, and a method of preventing or treating neurological diseases by administering the composition.
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: May 31, 2016
    Assignee: Industry-Academic Cooperation Foundation Gyeongsang National University
    Inventors: Myeong Ok Kim, M.L Narsimhan, M.L Naseer, R.A Bressan, Dae Jin Yun, Hae Young Lee
  • Patent number: 9314476
    Abstract: The present invention relates to a composition for treating or preventing neurodegenerative brain diseases comprising a black bean extract, and more particularly, to a composition for treating or preventing neurodegenerative brain diseases comprising a black bean extract or a fraction thereof, which comprises 15-25 wt % of delphinidin-3-glucoside, 65-80 wt % of cyanidin-3-glucoside and 5-10 wt % of petunidin-3-glucoside, a functional food composition for enhancing brain or cognitive function comprising the black bean extract or a fraction thereof, and a method for preparing the composition.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: April 19, 2016
    Assignee: Industry-Academic Cooperation Foundation Gyeongsang National University
    Inventor: Myeong Ok Kim
  • Publication number: 20140162968
    Abstract: The present invention relates to a method for screening and preparing an obesity prevention or treatment agent, and a method for preparing an obesity prevention or treatment agent. Being able to easily detect a substance that has a preventive and therapeutic effect on obesity, the present invention has a wide spectrum of applications in the research and medicine field in the prevention or treatment of obesity.
    Type: Application
    Filed: January 20, 2012
    Publication date: June 12, 2014
    Inventor: Myeong Ok Kim
  • Publication number: 20130210738
    Abstract: The present invention relates to a composition for preventing and treating neurological diseases, and more particularly to a composition for preventing and treating neurological diseases comprising osmotin, a health functional food composition for preventing and ameliorating neurological diseases comprising osmotin, and a method of preventing or treating neurological diseases by administering the composition.
    Type: Application
    Filed: December 24, 2010
    Publication date: August 15, 2013
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventors: Myeong Ok Kim, M.L Narsimhan, M.L Naseer, R.A Bressan, Dae Jin Yun, Hae Young Lee
  • Publication number: 20130109640
    Abstract: The present invention relates to a composition for treating or preventing neurodegenerative brain diseases comprising a black bean extract, and more particularly, to a composition for treating or preventing neurodegenerative brain diseases comprising a black bean extract or a fraction thereof, which comprises 15-25 wt % of delphinidin-3-glucoside, 65-80 wt % of cyanidin-3-glucoside and 5-10 wt % of petunidin-3-glucoside, a functional food composition for enhancing brain or cognitive function comprising the black bean extract or a fraction thereof, and a method for preparing the composition.
    Type: Application
    Filed: April 7, 2011
    Publication date: May 2, 2013
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
    Inventor: Myeong Ok Kim
  • Publication number: 20110071094
    Abstract: The present disclosure relates allose inducing programmed cell death in hormone refractory prostate cancer cell lines. More particularly, the present disclosure relates to a D-allose inducing programmed cell death in hormone refractory prostate cancer cell line of DU145 in dose-dependent manner by repressing cell growth and inhibiting cell cycle as well as by reducing expression of caspase-3 and poly (ADP-ribose) polymerase (PARP).
    Type: Application
    Filed: October 25, 2010
    Publication date: March 24, 2011
    Applicant: INDUSTRY-ACADEMIC COOPERATION FOUDATION, GYEONGSANG NATIONAL UNIVERSITY
    Inventors: MYEONG OK KIM, BONG CHUL CHUNG